An observational study in ADPKD and Pain, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Polycystic Kidney, Autosomal Dominant with a site in Belgium — 3 open to participants now, 7 under way, 2 of them phase 3. Polycystic Kidney, Autosomal Dominant · Belgium.
Among the 19 studies in Polycystic Kidney, Autosomal Dominant with a site in Belgium, this one is one of 3 that started in 2025, is one of 5 observational ones, and was the 18th registered.
185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.
Browse Polycystic Kidney, Autosomal Dominant studies →3 of the 19 studies in Polycystic Kidney, Autosomal Dominant with a site in Belgium are open now. Recruiting first, the newest first:
Calico Life Sciences LLC · Sites in Belgium, United States, Australia and 9 more countries
Ages 18–55
University Medical Center Groningen · Sites in Belgium, Austria, France and 4 more countries
Ages 18–80
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 12 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 10
First in 2007; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is close to the median of 150 across 45 observational studies indexed under Polycystic Kidney, Autosomal Dominant.
Median enrollment 270 across the 14 interventional studies, 407 across the 5 observational. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 19 have an industry lead sponsor. The 10 most frequent:
Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 965 studies on the registry; 268 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Universitaire Ziekenhuizen KU Leuven has 1 study filed under Polycystic Kidney, Autosomal Dominant — fewer than ten, so there is no comparison to draw.
4 of the studies in Polycystic Kidney, Autosomal Dominant with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06970028Universitaire Ziekenhuizen KU LeuvenSomatosensory Phenotyping of ADPKD | 2026-12 |
| NCT06747572Vertex Pharmaceuticals IncorporatedPolycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease | 2026-12-31 |
| NCT07161037Vertex Pharmaceuticals IncorporatedPhase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) | 2027-07-22 |
| NCT06734234GlaxoSmithKlineA Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease | 2027-07-23 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Polycystic Kidney, Autosomal Dominant with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Over 60% of patients with ADPKD suffer from pain, mostly in the abdomen, flank and back, often leading to the diagnosis. It is challenging to manage and cure the pain; approximately 39% of patients are not satisfied with their pain treatment, since the pain prevents them from doing various activities, affecting their quality of life. Pain can be present before enlargement of the kidneys, the source of the pain is often unknown and common analgesics are insufficient to manage the pain or cannot be taken due to renal impairment. By further investigating and characterizing the pain phenotype of the ADPKD population, pain management might be improved and alternative therapeutic approaches might be developed. In this clinical study, pain will be assessed in patients with ADPKD using Quantitative Sensory Testing (QST) on the dominant hand and the lower back, together with four questionnaires regarding pain and quality of life. These results will be compared with the somatosensory profile of matched healthy volunteers.
Patients with ADPKD from the University Hospitals Leuven will be included in this study. Additionally, healthy volunteers will be included using the registered database of the Center for Clinical Pharmacology (UZ Leuven).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with ADPKD
Healthy volunteers
Exclusion Criteria:
Patients with ADPKD
Healthy volunteers
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with ADPKD will be included (≥ 12 years old). The somatosensory profile will be described using Quantitative Sensory Testing and questionnaires regarding pain and quality of life.
Other: Quantitative Sensory Testing · Other: Questionnaires regarding pain and quality of life
Healthy volunteers will be included (≥ 12 years old), matched with the patient group based on age, sex and BMI. The somatosensory profile will be described using Quantitative Sensory Testing and the BPI-SF questionnaire.
Other: Quantitative Sensory Testing
We will perform QST on the dominant hand and lower back.
Questionnaires will be filled out by patients with ADPKD to evaluate pain and quality of life.
Somatosensory phenotyping of ADPKD using Quantitative Sensory Testing (QST)
The somatosensory phenotype of patients with ADPKD will be evaluated using QST on the dominant hand and lower back. These results will be compared with the somatosensory phenotype of matched healthy volunteers.
Time frame: Interval of ≤ 3 months between screening and study visit
Describing pain in ADPKD using the ADPKD-PDS questionnaire
(Potential) pain in the last 7 days will be assessed using the ADPKD-PDS questionnaire, which contains 20 questions (1-5 Likert scale) in 7 domains: Dull Pain Severity, Sharp Pain Severity, Discomfort Severity, Overall Pain and Discomfort Severity, Dull Pain Interference, Sharp Pain Interference, and Discomfort Interference. Unit of Measure: Total score per domain
Time frame: Interval of ≤ 3 months between screening and study visit
Describing neuropathic pain in ADPKD using the DN4 questionnaire
The DN4 questionnaire will be used to evaluate whether the (potential) pain is neuropathic. The questionnaire consists of 10 yes/no questions, in which a total score of 4/10 or higher is considered indicative of neuropathic pain. Unit of Measure: Total DN4 score (/10)
Time frame: Interval of ≤ 3 months between screening and study visit
Describing quality of life in ADPKD using the ADPKD-IS questionnaire
Quality of life will be assessed using the ADPKD-IS questionnaire, which consists of 18 questions (1-5 Likert scale) in 3 domains (physical, emotional, fatigue) and 4 additional elements (guilt, sleep, size/shape of abdomen, urinary frequency/urgency). Unit of Measure: Total score per domain/element
Time frame: Interval of ≤ 3 months between screening and study visit
Comparing pain between patients with ADPKD and healthy volunteers using the BPI-SF questionnaire
The BPI-SF questionnaire consists of 9 questions, concerning both the intensity and impact of pain on daily functioning in the last 24 hours. This questionnaire will be conducted in patients with ADPKD and healthy volunteers.
Time frame: Interval of ≤ 3 months between screening and study visit
Correlation between QST and questionnaires
A correlation between QST results and results from the questionnaires will be assessed in patients with ADPKD.
Time frame: Interval of ≤ 3 months between screening and study visit
Differences in somatosensory phenotype depending on the disease stage of ADPKD
Potential differences in somatosensory phenotype depending on the disease stage of patients with ADPKD (stage 1-5) will be evaluated using statistical analyses.
Time frame: Interval of ≤ 3 months between screening and study visit
Differences in somatosensory phenotype depending on the sex of patients with ADPKD
Potential differences in the somatosensory phenotype (QST) of female and male patients with ADPKD will be evaluated using statistical analyses.
Time frame: Interval of ≤ 3 months between screening and study visit
Differences in pain and quality of life depending on the sex of patients with ADPKD
Potential differences in pain and quality of life, described using questionnaires, of female and male patients with ADPKD will be evaluated using statistical analyses.
Time frame: Interval of ≤ 3 months between screening and study visit
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Polycystic Kidney, Autosomal Dominant →
Universitaire Ziekenhuizen KU Leuven →